News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,577 Results
Type
Article (43792)
Company Profile (286)
Press Release (673499)
Section
Business (209300)
Career Advice (2099)
Deals (36032)
Drug Delivery (98)
Drug Development (83599)
Employer Resources (173)
FDA (16721)
Job Trends (15272)
News (354466)
Policy (33672)
Tag
2024 BioCapital Digital (7)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (6)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (6)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2724)
Accelerated approval (2)
Adcomms (24)
Allergies (81)
Alliances (51103)
ALS (81)
Alzheimer's disease (1376)
Antibody-drug conjugate (ADC) (105)
Approvals (16696)
Artificial intelligence (226)
Autoimmune disease (11)
Automation (14)
Bankruptcy (364)
Best Places to Work (11933)
BIOSECURE Act (19)
Biosimilars (98)
Biotechnology (198)
Bladder cancer (56)
Brain cancer (28)
Breast cancer (239)
Cancer (1858)
Cardiovascular disease (142)
Career advice (1755)
Career pathing (30)
CAR-T (136)
Cell therapy (392)
Cervical cancer (13)
Clinical research (67355)
Collaboration (727)
Compensation (393)
Complete response letters (21)
COVID-19 (2687)
CRISPR (34)
C-suite (187)
Cystic fibrosis (102)
Data (1737)
Decentralized trials (2)
Denatured (16)
Depression (40)
Diabetes (234)
Diagnostics (6502)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (108)
Drug pricing (97)
Drug shortages (25)
Duchenne muscular dystrophy (65)
Earnings (86590)
Editorial (30)
Employer branding (23)
Employer resources (150)
Events (114961)
Executive appointments (603)
FDA (17733)
Featured Employer (57)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (658)
Gene editing (89)
Generative AI (24)
Gene therapy (273)
GLP-1 (705)
Government (4526)
Grass and pollen (4)
Guidances (46)
Healthcare (19422)
Huntington's disease (24)
IgA nephropathy (22)
Immunology and inflammation (97)
Indications (23)
Infectious disease (2811)
Inflammatory bowel disease (130)
Inflation Reduction Act (8)
Influenza (44)
Intellectual property (73)
Interviews (328)
IPO (16711)
IRA (40)
Job creations (3790)
Job search strategy (1494)
Kidney cancer (10)
Labor market (26)
Layoffs (468)
Leadership (16)
Legal (8130)
Liver cancer (70)
Lung cancer (269)
Lymphoma (122)
Machine learning (2)
Management (58)
Manufacturing (254)
MASH (58)
Medical device (13896)
Medtech (13901)
Mergers & acquisitions (19723)
Metabolic disorders (612)
Multiple sclerosis (64)
NASH (18)
Neurodegenerative disease (76)
Neuropsychiatric disorders (23)
Neuroscience (1828)
NextGen: Class of 2025 (6762)
Non-profit (4688)
Northern California (2242)
Now hiring (35)
Obesity (337)
Opinion (202)
Ovarian cancer (64)
Pain (76)
Pancreatic cancer (72)
Parkinson's disease (120)
Partnered (17)
Patents (183)
Patient recruitment (82)
Peanut (49)
People (58888)
Pharmaceutical (72)
Pharmacy benefit managers (18)
Phase I (21018)
Phase II (29662)
Phase III (22085)
Pipeline (821)
Podcasts (45)
Policy (104)
Postmarket research (2640)
Preclinical (8887)
Press Release (68)
Prostate cancer (85)
Psychedelics (35)
Radiopharmaceuticals (250)
Rare diseases (354)
Real estate (6156)
Recruiting (66)
Regulatory (22876)
Reports (43)
Research institute (2480)
Resumes & cover letters (359)
Rett syndrome (2)
RNA editing (1)
RSV (37)
Schizophrenia (61)
Series A (121)
Series B (73)
Service/supplier (11)
Sickle cell disease (52)
Southern California (1918)
Special edition (13)
Sponsored (29)
Startups (3724)
State (2)
Stomach cancer (12)
Supply chain (59)
The Weekly (28)
United States (19875)
Vaccines (663)
Venture capitalists (34)
Webinars (12)
Weight loss (235)
Women's health (31)
Worklife (13)
Date
Today (174)
Last 7 days (776)
Last 30 days (3021)
Last 365 days (35283)
2025 (5857)
2024 (36185)
2023 (41082)
2022 (52366)
2021 (56938)
2020 (55467)
2019 (48263)
2018 (36466)
2017 (33365)
2016 (32949)
2015 (38936)
2014 (32624)
2013 (27607)
2012 (29732)
2011 (30433)
2010 (28407)
Location
Africa (772)
Alabama (49)
Alaska (7)
Arizona (219)
Arkansas (12)
Asia (39189)
Australia (6486)
California (5129)
Canada (1782)
China (423)
Colorado (231)
Connecticut (247)
Delaware (114)
Europe (86485)
Florida (746)
Georgia (175)
Hawaii (1)
Idaho (57)
Illinois (483)
India (20)
Indiana (281)
Iowa (7)
Japan (128)
Kansas (100)
Kentucky (23)
Louisiana (9)
Maine (67)
Maryland (792)
Massachusetts (3941)
Michigan (202)
Minnesota (361)
Mississippi (2)
Missouri (73)
Montana (30)
Nebraska (25)
Nevada (54)
New Hampshire (62)
New Jersey (1449)
New Mexico (29)
New York (1471)
North Carolina (915)
North Dakota (8)
Northern California (2242)
Ohio (181)
Oklahoma (13)
Oregon (36)
Pennsylvania (1163)
Puerto Rico (7)
Rhode Island (24)
South America (1147)
South Carolina (13)
South Dakota (1)
Southern California (1918)
Tennessee (86)
Texas (750)
Utah (160)
Virginia (121)
Washington D.C. (57)
Washington State (491)
West Virginia (3)
Wisconsin (45)
717,577 Results for "alfa scientific designs inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
March 5, 2025
·
4 min read
Press Releases
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
January 9, 2025
·
6 min read
BioMidwest
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia.
June 26, 2024
·
13 min read
Press Releases
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)
February 17, 2025
·
4 min read
Press Releases
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 6, 2025
·
9 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Press Releases
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
January 27, 2025
·
5 min read
Press Releases
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
February 12, 2025
·
6 min read
Press Releases
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
December 27, 2024
·
8 min read
Genetown
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda (TSE: 4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.
March 26, 2024
·
12 min read
1 of 71,758
Next
